clinical trial · NCT06465186
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Merck Sharp & Dohme LLC·phase2·active not recruiting·n = 80
Non-alcoholic Fatty Liver DiseaseNonalcoholic SteatohepatitisNAFLDMetabolic Dysfunction-associated Steatotic Liver DiseaseMetabolic Dysfunction-associated SteatohepatitisEfinopegdutidePlacebo
brief summary
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn: * If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver * About the safety of efinopegdutide and how well people tolerate it
started
Jul 12, 2024
primary completion
Aug 6, 2026
completion
Aug 6, 2026
last updated
Mar 2, 2026
official title
Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol